Cytek Biosciences, Inc. CTKB Business Segments — Amortization - license & IP expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept ctkb:AmortizationLicenseAndIPExpense.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s business segments — amortization - license & ip expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s business segments — amortization - license & IP expense?
- Cytek Biosciences, Inc. (CTKB) reported business segments — amortization - license & IP expense of $481K in Q1 2026.
- How has Cytek Biosciences, Inc.'s business segments — amortization - license & IP expense changed year-over-year?
- Cytek Biosciences, Inc.'s business segments — amortization - license & IP expense decreased by 2.4% year-over-year, from $493K to $481K.
- What is the long-term trend for Cytek Biosciences, Inc.'s business segments — amortization - license & IP expense?
- Over 3 years (2022 to 2025), Cytek Biosciences, Inc.'s business segments — amortization - license & IP expense has grown at a 17.8% compound annual growth rate (CAGR), from $1.18M to $1.94M.
- What does business segments — amortization - license & IP expense mean?
- Reflects the systematic allocation of the cost of intangible assets, such as licenses and intellectual property, over their useful lives. This non-cash expense highlights the capital investment required to maintain the segment's technological competitive advantage.